Search results for "HEPATITIS C VIRUS"

showing 10 items of 403 documents

Solitary polypoid laryngeal xanthoma.

2013

We report the case of a 51-year-old male smoker with diabetes mellitus and hyperlipidaemia and a long history of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection treated with various antiretroviral regimes, who was referred to the otolaryngology department with progressive dysphonia. Fibre-optic laryngoscopy showed a solitary, yellowish-white pedunculated polyp on the anterior third of the left cord, with no other abnormality. Pathological analysis revealed a polypoid laryngeal xanthoma that was immunoreactive against CD68, perilipin, and adipophilin. This unusual laryngeal lesion in the clinical context of our patient suggests a possible role of antiretroviral treatment…

Pathologymedicine.medical_specialtyCordmedicine.diagnostic_testbusiness.industryHepatitis C virusLaryngoscopyContext (language use)Case ReportGeneral MedicineXanthomamedicine.diseasemedicine.disease_causelcsh:Otorhinolaryngologylcsh:RF1-547PathogenesisDiabetes mellitusMedicinebusinessPathologicalCase reports in otolaryngology
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct

Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals

2006

In healthy individuals, natural and adaptive immune responses are able to control virus entry into the host. In particular, CD8(+)-mediated cytotoxicity, sustained by the intervention of CD4+ cells, represents the major key event leading to virus eradication. On the other hand, viruses are able to evade from host immune response via several mechanisms, and special emphasis will be placed on hepatitis C virus and chronic Epstein-Barr infections also in view of personal data. Virokines, viroreceptors, and serpins greatly contribute to viral immune escape, and, among virokines, interleukin (IL)-10 has been object of intensive studies. Finally, all these products have been used as biopharmaceut…

PharmacologyHepatitis C virusOrganic ChemistryInterleukinVirus Physiological PhenomenaBiologymedicine.disease_causeAntiviral AgentsBiochemistryVirologyVirusViral ProteinsImmune systemViral entryVirusesDrug DiscoveryImmunologyAntigenic variationmedicineHumansMolecular MedicineCD8Virus Physiological PhenomenaCurrent Medicinal Chemistry
researchProduct

2015

ABSTRACT Dengue fever is a severe, widespread, and neglected disease with more than 2 million diagnosed infections per year. The dengue virus NS2B/NS3 protease (PR) represents a prime target for rational drug design. At the moment, there are no clinical PR inhibitors (PIs) available. We have identified diaryl (thio)ethers as candidates for a novel class of PIs. Here, we report the selective and noncompetitive inhibition of the serotype 2 and 3 dengue virus PR in vitro and in cells by benzothiazole derivatives exhibiting 50% inhibitory concentrations (IC 50 s) in the low-micromolar range. Inhibition of replication of DENV serotypes 1 to 3 was specific, since all substances influenced neither…

PharmacologyNS3ProteasevirusesHepatitis C virusmedicine.medical_treatmentIn vitro toxicologyDengue virusBiologymedicine.disease_causemedicine.diseaseVirologyIn vitroDengue feverInfectious DiseasesViral replicationmedicinePharmacology (medical)Antimicrobial Agents and Chemotherapy
researchProduct

Interferon-?? Alone versus Interferon-?? plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-?? Treatment

2000

Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of outpatients at 3 centres in Palermo, Sicily, Italy. Patients and participants: We recruited 72 patients (48 males, 24 females), mean age 48.8 ± 6.6 years (range 31 to 63 years), with biopsy-proven chronic hepatitis C, predominantly genotype lb. Interventions: 24 patients (group A) received IFNα 6MU 3 times weekly for 6 months, and 48 patients (group B) received IFNα 6MU 3 times weekly + ribavirin 1200 mg/day fo…

Pharmacologymedicine.medical_specialtyCombination therapybusiness.industryRibavirinHepatitis C virusAlpha interferonGeneral Medicinemedicine.disease_causeGastroenterologydigestive system diseasesGroup Bchemistry.chemical_compoundchemistryInterferonInternal medicineAbsolute neutrophil countMedicinePharmacology (medical)businessAdverse effectBiotechnologymedicine.drugBioDrugs
researchProduct

Genetic Analysis of Sequences in the 3′ Nontranslated Region of Hepatitis C Virus That Are Important for RNA Replication

2002

ABSTRACT The genome of the hepatitis C virus (HCV) is a plus-strand RNA molecule that carries a single long open reading frame. It is flanked at either end by highly conserved nontranslated regions (NTRs) that mediate crucial steps in the viral life cycle. The 3′ NTR of HCV has a tripartite structure composed of an about 40-nucleotide variable region, a poly(U/UC) tract that has a heterogeneous length, and a highly conserved 98-nucleotide 3′-terminal sequence designated the X tail or 3′X. Conflicting data as to the role the sequences in the 3′ NTR play in RNA replication have been reported. By using the HCV replicon system, which is based on the self-replication of subgenomic HCV RNAs in hu…

Poly URNA StabilityHepatitis C virusImmunologyMolecular Sequence DataRNA-dependent RNA polymeraseReplicationHepacivirusBiologymedicine.disease_causeMicrobiologychemistry.chemical_compoundVirologymedicineTumor Cells CulturedHumansReplicon3' Untranslated RegionsSubgenomic mRNAGeneticsBase SequenceThree prime untranslated regionRNAVirologychemistryMutagenesisInsect ScienceNucleic Acid ConformationRNA ViralCytosine
researchProduct

Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy

2010

Predictive markerHepatologybusiness.industryFibrosisHepatitis C virusMedicinebusinessmedicine.diseasemedicine.disease_causeVirologyHepatology
researchProduct

Unequal distribution of RT-PCR artifacts along the E1-E2 region of Hepatitis C virus.

2009

Although viral variability studies have focused traditionally on consensus sequences, the relevance of molecular clone sequences for studying viral evolution at the intra-host level is being increasingly recognized. However, for this approach to be reliable, RT-PCR artifacts do not have to contribute excessively to the observed variability. Molecular clone sequences were obtained from an in vitro transcript to estimate the maximum error rate associated to RT-PCR for the Hepatitis C virus (HCV) E1-E2 region. On average, the frequency of RT-PCR errors was one order of magnitude lower than the level of intra-host genetic variability observed in samples from an HCV outbreak. However, RT-PCR err…

RNA virusHepatitis C virusMutational hotspotHepacivirusBiologymedicine.disease_causeDisease OutbreaksViral Envelope ProteinsVirologyGenetic variationmedicineConsensus sequenceSequencingHumansGenetic variabilityVariabilityGeneticsReverse Transcriptase Polymerase Chain ReactionMolecular cloningRNA virusbiology.organism_classificationHepatitis CReverse transcriptaseHypervariable regionHypervariable regionViral evolutionRNA ViralArtifactsJournal of virological methods
researchProduct

Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection.

2016

The treatment of HCV infection has seen significant progress, particularly since the approval of new direct-acting antiviral drugs. However these clinical achievements have been made despite an incomplete understanding of HCV replication and within-host evolution, especially compared with HIV-1. Here, we undertake a comprehensive analysis of HCV within-host evolution during chronic infection by investigating over 4000 viral sequences sampled longitudinally from 15 HCV-infected patients. We compare our HCV results to those from a well-studied HIV-1 cohort, revealing key differences in the evolutionary behaviour of these two chronic-infecting pathogens. Notably, we find an exceptional level o…

RNA viruses0301 basic medicineMaleHepacivirusHIV InfectionsHepacivirusPathology and Laboratory Medicinemedicine.disease_causeVirus ReplicationHepatitis0302 clinical medicineImmunodeficiency VirusesMedicine and Health Sciences2.2 Factors relating to the physical environmentChronicAetiologylcsh:QH301-705.5Data Managementeducation.field_of_studybiologyHepatitis C virusLiver Diseasevirus diseasesHepatitis C3. Good healthPhylogeneticsInfectious DiseasesMedical MicrobiologyViral PathogensViral evolutionVirusesEvolutionary RateHIV/AIDS030211 gastroenterology & hepatologyFemalePathogensInfectionResearch Articlelcsh:Immunologic diseases. AllergyComputer and Information SciencesEvolutionary ProcessesEvolutionHepatitis C virusPopulationChronic Liver Disease and CirrhosisImmunologyMicrobiologyViral EvolutionVirusEvolution Molecular03 medical and health sciencesHepatitis - CVirologyRetrovirusesGeneticsmedicineHumansEvolutionary SystematicsEvolutionary dynamicseducationMicrobial PathogensMolecular BiologyTaxonomyEvolutionary BiologyFlavivirusesPopulation BiologyLentivirusOrganismsBiology and Life SciencesHIVMolecularHepatitis C Chronicbiology.organism_classificationVirologyHepatitis virusesOrganismal EvolutionViral ReplicationChronic infection030104 developmental biologyEmerging Infectious Diseaseslcsh:Biology (General)Viral replicationMicrobial EvolutionImmunologyHIV-1Parasitologylcsh:RC581-607Digestive DiseasesPopulation GeneticsFollow-Up Studies
researchProduct

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

2016

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cas…

RNA virusesDecision AnalysisPhysiologyEconomicsCost-Benefit AnalysisSocial Scienceslcsh:MedicineBlood DonorsHepacivirusmedicine.disease_causeBiochemistryHepatitis0302 clinical medicineImmune Physiology030212 general & internal medicineChroniclcsh:SciencePathology and laboratory medicinehealth care economics and organizationsMultidisciplinaryImmune System ProteinsCost–benefit analysisHepatitis C virusLiver DiseaseCost-effectiveness analysisMedical microbiologyHepatitis CHCV AntibodyInfectious DiseasesVirusesEngineering and TechnologyBlood Banks030211 gastroenterology & hepatologyPathogensInfectionManagement EngineeringResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyHepatitis C virusImmunologyCost-Effectiveness AnalysisImmunoblottingChronic Liver Disease and CirrhosisMolecular Probe TechniquesAntibody levelResearch and Analysis MethodsMicrobiologyAntibodies03 medical and health sciencesChronic hepatitisHepatitis - CClinical ResearchInternal medicineparasitic diseasesmedicineHumansImmunoassaysMolecular Biology TechniquesSensitivity analysesMolecular BiologyMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryDecision Treeslcsh:RHepatitis C antibodyOrganismsViral pathogensProteinsHepatitis C ChronicHepatitis C AntibodiesHepatitis virusesEconomic AnalysisMicrobial pathogensHealth CareEmerging Infectious DiseasesCost Effectiveness ResearchHealth Care FacilitiesImmunologyImmunologic Techniqueslcsh:QbusinessDigestive Diseases
researchProduct